


**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/982,172	
(use as many sheets as necessary)			Filing Date	October 19, 200	
			First Named Inventor	KATZ et al	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	Attorney Docket Number	01/22283	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
CA	BA	Marks et al, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>Bio/technology</i> , 10:779-783, 1992			
	BB	Söderlind et al, "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination", <i>Immunotechnology</i> , 4:279-285, 1999			
	BC	Söderlind et al, "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries", <i>Nature Biotechnology</i> , 18:852-856, 2000			
	BD	Ohlin et al, Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition", <i>Molecular Immunology</i> , 33(1):47-56, 1996			
	BE	Hemminki et al, "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs", <i>Immunotechnology</i> , 4:59-69, 1998			
	BF	Barbas III et al, "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site", <i>Proc. Natl. Acad. Sci. USA</i> , 88:7978-7982, 1991			
	BG	Hoogenboom et al, "Antibody Phage Display Technology and its Applications", <i>Molecular Immunology</i> , 4:1-20, 1998			
	BH	Haupt et al, "Plastic Antibodies: Developments and Applications", <i>Trends Biotech.</i> , 16:468-476, 1998			
CA	BI	Vlatakis et al, "Drug Assay Using Antibody Mimics Made by Molecular Imprinting", <i>Nature</i> , 361:645647, 1993			
	<del>BJ</del>	<del>Arnon, R., "Synthetic Peptides as the Basis for Vaccine Design", <i>Molecular Immunology</i>, no further info given.</del>			
CA	BK	Arnheiter et al, "Physicochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon" <i>Nature</i> , 294:278-280, 1981			
	BL	Mariani et al, "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein", <i>Molecular Immunology</i> , 24(3):297-303, 1987			
	BM	Chames et al, "Antibody Engineering and its Applications in Tumor Targeting and Intracellular Immunization", <i>FEMS Microbiology Letters</i> , 189:1-8, 2000			
	BN	Hoogenboom et al, "Natural and Designer Binding Sites Made by Phage Display Technology", <i>Immunology Today</i> , 21(8):371-378, 2000			
	BO	Nelson et al, "Demystified... Monoclonal Antibodies", <i>J. Clin. Pathol.: Mol Pathol.</i> , 53:111-117, 2000			
	BP	Li, Min, "Applications of Display Technology in Protein Analysis", <i>Nature Biotechnology</i> , 18:1251-1256, 2000			
CA	BQ	Borrebaeck, Carl A.K., "Antibodies in Diagnostics-From Immunoassays to Protein Chips", <i>Immunology Today</i> , 21(8):379-381, 2000			
Examiner Signature				Date Considered	3/15/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

